Results 71 to 80 of about 1,259,388 (355)

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO [PDF]

, 2001
A prospective, multicenter, randomized trial was undertaken to compare the efficacy and toxicity of adriamycin with mitoxantrone within a 6-drug combination chemotherapy regimen for elderly patients (older than 60 years) with high-grade non-Hodgkin ...
Cunningham, D., Gregory, W., Hancock, B., Hoskin, P., Hudson, G.V., Linch, D., MacLennan, K., Mainwaring, P.N., Norton, A.J., Smith, P.   +9 more
core   +1 more source

The Role of Invasive Procedures in the Treatment of Complicated Gastrointestinal Graft‐Versus‐Host Disease in Pediatric Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Gastrointestinal graft‐versus‐host disease (GI GVHD) following hematopoietic stem cell transplant is typically managed with medical therapy, but surgery and angioembolization may be warranted in selected cases with life‐threatening complications.
Gaia Brunetti, Giorgio Persano, Chiara Grimaldi, Pier Luigi Di Paolo, Carmen Malaspina, Francesco Quagliarella, Valerio Balassone, Anna Chiara Iolanda Contini, Gian Luigi Natali, Rita Alaggio, Ivan Pietro Aloi, Tamara Caldaro, Alessandro Crocoli   +12 more
wiley   +1 more source

Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider, Amelie Alfert, Marc Hotfilder, Birgit Burkardt, Marcel te Vrugt   +4 more
wiley   +1 more source

Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

Hematology Reports, 2020
The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8-10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen
Rafiye Ciftciler, Hakan Goker, Yahya Buyukasik, Nilgun Sayınalp, Ibrahim C. Haznedaroglu, Salih Aksu, Osman Ozcebe, Haluk Demiroglu   +7 more
doaj   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo   +7 more
wiley   +1 more source

Behavioral Model of Middle-Aged and Seniors for Bicycle Tourism

Frontiers in Psychology, 2020
This research centers on the behavioral tendency of the middle-aged and seniors in bicycle tourism at environmentally protected scenic areas and its relevant influence factors.
Shu-Wang Lin, Shih-Yun Hsu, Juei-Ling Ho, Mei-Ying Lai   +3 more
doaj   +1 more source

Comparing the Daily Versus the Intermittent Regimens of the Anti-Tubercular Chemotherapy in the Initial Intensive Phase in Non-HIV, Sputum Positive, Pulmonary Tuberculosis Patients [PDF]

Journal of Clinical and Diagnostic Research, 2013
Background: Tuberculosis (TB) is a major health problem in the universe and India is no longer exempted from this crisis. The emergence of HIV and MDRTB (Multi Drug Resistant Tuberculosis) have further made the situation critical. Aims: Our aim was to
Pranab Kumar Mandal, Abhijit Mandal, Sujit Kumar Bhattacharyya   +2 more
doaj   +1 more source

Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis [PDF]

, 2013
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens.
A Talbot, AJ Viera, Annemarie M. J. Wensing, AR Zolopa, Axel Fun, B Grinsztejn, B Taiwo, B Young, C Cohen, C Garrido, D McMahon, D Moher, DK Owens, DV Cordery, E DeJesus, E Martinez, E Vispo, EM Gardner, F Caby, F Canducci, F Smith, H Byakwaga, H Hatano, J Reynes, J van Lunzen, JJ Eron, JJ Eron Jr, JK Rockstroh, JL Lennox, JL Lennox, JM Gatell, JM Molina, JR Santos, L Van Wesenbeeck, L Wittkop, Linos Vandekerckhove, Luis Menéndez-Arias, M Harris, M Markowitz, M Markowitz, MA Thompson, MJ Buzon, MJ Kozal, Monique Nijhuis, N Mantel, Nele Brusselaers, O Goethals, PE Sax, Peter Messiaen, R Qaqish, R Relevo, RT Gandhi, RT Gandhi, RT Steigbigel, RT Steigbigel, S Gallien, S Nozza, V Dahl, W Towner, Y Yazdanpanah   +59 more
core   +4 more sources

Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10‐Year, Single‐Institution Experience Encompassing the COVID‐19 Pandemic

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa, Shou Xu, Mark Zobeck, Sarah E. Sartain, Nino Rainusso, Lisa Wang, Nicole Montgomery, Paige Wheaton, Sarah Whittle   +8 more
wiley   +1 more source

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources